Details of Drug

Details of Drug

 Drug General Information (ID: D0278)
  Drug Name
Cefditoren
  Drug Type Small molecule
  Drug Synonymous
Cefditoren [USAN:INN]; Meiact (TN); Spectracef (TN); (+)-(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-3-((Z)-2-(4-methyl-5-thiazolyl)vinyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime); (6R-(3(Z),6alpha,7beta(Z)))-7-((2-Amino-4-thiazolyl)(methoxyimino)acetyl)amino-3-(2-(4-methyl-5-thiazolyl)ethenyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
    Click to Show/Hide
  Disease Class 1A00-1C4Z: Bacterial infection
  Therapeutic Class Antibiotics
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C19H18N6O5S3
  InChI 1S/C19H18N6O5S3/c1-8-11(33-7-21-8)4-3-9-5-31-17-13(16(27)25(17)14(9)18(28)29)23-15(26)12(24-30-2)10-6-32-19(20)22-10/h3-4,6-7,13,17H,5H2,1-2H3,(H2,20,22)(H,23,26)(H,28,29)/b4-3-,24-12-/t13-,17-/m1/s1
  InChIKey KMIPKYQIOVAHOP-YLGJWRNMSA-N
  Canonical SMILES CC1=C(SC=N1)C=CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O
  External Link
Pubchem ID 9870843
CAS Number 104145-95-1
CHEBI ID 59343
TTD ID D0E3RW
VARIDT ID DR01394

Drug-Drug Interaction Network
  Sunburst Graph
AM001  Affected gastrointestinal absorption
AM003  Affected organization distribution
AM005  Affected excretion pathways
AM006  Pharmacodynamic additive effects
AM007  Pharmacodynamic antagonistic effects
BM002  Altered intestinal flora
BM005  Altered gastric pH
BM014  Interference of cell/tissue uptake
BM028  Competitive inhibition of renal tubular secretion
BM031  Increased renal excretion (Unspecific)
BM050  Increased risk of bleeding
BM100  Antagonize the effect of vaccine/toxoid
BM107  Attenuated pharmacological effects (Unspecific)
  Relation Graph
 Full list of drugs interacting with Cefditoren
      Affected gastrointestinal absorption
   Altered intestinal flora Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1094
 
Mycophenolate mofetil
 
C23H31NO7
 
5281078 
Moderate    Inter Info   
[25], [26]
D1095
 
Mycophenolic acid
 
C17H20O6
 
446541 
Moderate    Inter Info   
[25], [26]
   Altered gastric pH Drug Num:  20
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0049
 
Aluminum hydroxide
 
AlH3O3
 
10176082 
Moderate    Inter Info   
[13]
D0236
 
Calcium carbonate
 
CCaO3
 
10112 
Moderate    Inter Info   
[13]
D0458
 
Dexlansoprazole
 
C16H14F3N3O2S
 
9578005 
Moderate    Inter Info   
[13]
D0967
 
Magaldrate
 
AlHMgO5S+2
 
3086011 
Moderate    Inter Info   
[13]
D0968
 
Magnesium carbonate
 
CMgO3
 
11029 
Moderate    Inter Info   
[13]
D0973
 
Magnesium hydroxide
 
H2MgO2
 
14791 
Moderate    Inter Info   
[13]
D0974
 
Magnesium oxide
 
MgO
 
14792 
Moderate    Inter Info   
[13]
D1373
 
Rabeprazole
 
C18H21N3O3S
 
5029 
Moderate    Inter Info   
[13]
D1480
 
Sodium bicarbonate
 
CHNaO3
 
516892 
Moderate    Inter Info   
[13]
D1483
 
Sodium citrate
 
C6H5Na3O7
 
6224 
Moderate    Inter Info   
[13]
D0337
 
Cimetidine
 
C10H16N6S
 
2756 
Moderate    Inter Info   
[13]
D0483
 
Didanosine
 
C10H12N4O3
 
135398739 
Moderate    Inter Info   
[13]
D0603
 
Esomeprazole
 
C17H19N3O3S
 
9568614 
Moderate    Inter Info   
[13]
D0636
 
Famotidine
 
C8H15N7O2S3
 
5702160 
Moderate    Inter Info   
[13]
D0892
 
Lansoprazole
 
C16H14F3N3O2S
 
3883 
Moderate    Inter Info   
[13]
D1151
 
Nizatidine
 
C12H21N5O2S2
 
3033637 
Moderate    Inter Info   
[13]
D1179
 
Omeprazole
 
C17H19N3O3S
 
4594 
Moderate    Inter Info   
[13]
D1222
 
Pantoprazole
 
C16H15F2N3O4S
 
4679 
Moderate    Inter Info   
[13]
D1381
 
Ranitidine
 
C13H22N4O3S
 
3001055 
Moderate    Inter Info   
[13]
D1382
 
Ranitidine (bismuth citrate)
 
C13H22N4O3S
 
3001055 
Moderate    Inter Info   
[13]
      Affected organization distribution
   Interference of cell/tissue uptake Drug Num:  1
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1817
 
Indium In-111 oxyquinoline
 
C27H18InN3O3
 
16685037 
Moderate    Inter Info   
[17]
      Affected excretion pathways
   Competitive inhibition of renal tubular secretion Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0576
 
Entecavir
 
C12H15N5O3
 
135398508 
Moderate    Inter Info   
[24]
D1241
 
Pemetrexed
 
C20H21N5O6
 
135410875 
Moderate    Inter Info   
[27]
   Increased renal excretion (Unspecific) Drug Num:  4
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0217
 
Bumetanide
 
C17H20N2O5S
 
2471 
Moderate    Inter Info   
[5], [6], [7], [8], [9], [10], [11], [12]
D0613
 
Etacrynic acid
 
C13H12Cl2O4
 
3278 
Moderate    Inter Info   
[5], [6], [9]
D0704
 
Furosemide
 
C12H11ClN2O5S
 
3440 
Moderate    Inter Info   
[5], [6], [7], [8], [9], [10], [11], [12]
D1611
 
Torasemide
 
C16H20N4O3S
 
41781 
Moderate    Inter Info   
[5], [6], [9]
      Pharmacodynamic additive effects
   Increased risk of bleeding Drug Num:  3
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0087
 
Anisindione
 
C16H12O3
 
2197 
Moderate    Inter Info   
[14], [15], [16]
D0481
 
Dicoumarol
 
C19H12O6
 
54676038 
Moderate    Inter Info   
[14], [15], [16]
D1711
 
Warfarin
 
C19H16O4
 
54678486 
Moderate    Inter Info   
[14], [15], [16]
      Pharmacodynamic antagonistic effects
   Antagonize the effect of vaccine/toxoid Drug Num:  2
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1914
 
Typhoid vaccine (live)
 
NA
 
NA
Major    Inter Info   
[1], [2], [3]
D1693
 
Vibrio cholerae CVD 103-HgR strain live antigen (live)
 
NA
 
NA
Major    Inter Info   
[4]
   Attenuated pharmacological effects (Unspecific) Drug Num:  4
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D1011
 
Mestranol
 
C21H26O2
 
6291 
Moderate    Inter Info   
[18], [19], [20]
D0313
 
Chloramphenicol
 
C11H12Cl2N2O5
 
5959 
Moderate    Inter Info   
[21], [22], [23]
D0606
 
Estradiol
 
C18H24O2
 
5757 
Moderate    Inter Info   
[18], [19], [20]
D0619
 
Ethinylestradiol
 
C20H24O2
 
5991 
Moderate    Inter Info   
[18], [19], [20]
References
1 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
2 UK government "Typhoid.".
3 American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association (1994).
4 Product Information. Vaxchora (cholera vaccine, live). PaxVax, Miami, FL.
5 Chrysos G, Gargalianos P, Lelekis M, Stefanou J, Kosmidis J "Pharmacokinetic interactions of ceftazidime and frusemide." J Chemother 7 Suppl (1995): 107-10. [PMID: 8904125]
6 Dodds MG, Foord RD "Enhancement by potent diuretics of renal tubular necrosis induced by cephaloridine." Br J Pharmacol 40 (1970): 227-36. [PMID: 5492895]
7 Korn A, Eichler HG, Gasic S "A drug interaction study of ceftriaxone and frusemide in healthy volunteers." Int J Clin Pharmacol Ther Toxicol 24 (1986): 262-4. [PMID: 3733274]
8 Lawson DH, Macadam RF, Singh H, et al "Effect of furosemide on antibiotic-induced renal damage in rats." J Infect Dis 126 (1972): 593-600. [PMID: 4664116]
9 Norrby R, Stenqvist K, Elgefors B "Interaction between cephaloridine and furosemide in man." Scand J Infect Dis 8 (1976): 209-12. [PMID: 968459]
10 Simpson IJ "Nephrotoxicity and acute renal failure associated with cephalothin and cephaloridine." N Z Med J 74 (1971): 312-5. [PMID: 5289757]
11 Tilstone WJ, Semple PF, Lawson DH, Boyle JA "Effects of furosemide on glomerular filtration rate and clearance of practolol, digoxin, cephaloridine, and gentamicin." Clin Pharmacol Ther 22 (1977): 389-94. [PMID: 902451]
12 Trollfors B, Norrby R, Kristianson K, Nilsson NJ "Effects on renal function of treatment with cefoxitin alone or in combination with furosemide." Scand J Infect Dis 13 (1978): 73-7. [PMID: 356182]
13 Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
14 Product Information. Suprax (cefixime). Lupin Pharmaceuticals Inc, Baltimore, MD.
15 Wood T, Johnson K, Naylor S, Weinshilboum R "Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in humantissue: possible relationship to hypoprothrombinemia." Drug Metab Dispos 30 (2002): 1123-1128
16 Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976): 91-3
17 Product Information. Indium Oxyquinoline In-111 (indium oxyquinoline In-111). GE Healthcare, Princeton, NJ.
18 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
19 Barnett ML "Inhibition of oral contraceptive effectiveness by concurrent antibiotic administration." J Periodontol 56 (1985): 18-20. [PMID: 3882930]
20 King VJ "OC failure rates and oral antibiotics." J Fam Pract 45 (1997): 104-5. [PMID: 9267366]
21 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA."
22 Asmar BI, Prainito M, Dajani AS "Antagonistic effect of chloramphenicol in combination with cefotaxime or ceftriaxone." Antimicrob Agents Chemother 32 (1988): 1375-8
23 Brown TH, Alford RH "Antagonism by chloramphenicol of broad-spectrum beta-lactam antibiotics against Klebsiella pneumoniae." Antimicrob Agents Chemother 25 (1984): 405-7
24 Product Information. Baraclude (entecavir). Bristol-Myers Squibb, Princeton, NJ.
25 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
26 Product Information. Myfortic (mycophenolic acid). Novartis Pharmaceuticals, East Hanover, NJ.
27 Product Information. Alimta (pemetrexed). Lilly, Eli and Company, Indianapolis, IN.